3D bioprinting in 2026 has moved decisively from academic promise to translational execution. What began as exploratory tissue fabrication a decade ago is now intersecting with regulated manufacturing, clinical trial design, and reimbursement strategy in the United States. The field’s trajectory reflects not only technical progress in bioinks and printing precision, but also a maturing … Read more
Lab-grown tissue innovations are gaining investment momentum across the United States as regenerative medicine moves from experimental science toward structured commercialization. Venture capital firms, strategic pharmaceutical partners, and public funding agencies are increasingly backing companies developing engineered tissues for therapeutic transplantation, drug testing, and disease modeling. This capital influx reflects confidence in platform scalability, regulatory … Read more